Anonymous
Guest
Anonymous
Guest
LOL - looks like Amgen still hasn't learned from the Prolia approval process and launch - what a shame. I'm guessing we harshly labeled our own new drug Repatha - High Risk or select patient types ....
LOL - looks like Amgen still hasn't learned from the Prolia approval process and launch - what a shame. I'm guessing we harshly labeled our own new drug Repatha - High Risk or select patient types ....